Projects

Projects

Tumor Necrosis Factor - alpha (TNFa) inhibiting compound as a first in class drug treatment for neuroinflammatory diseases.

The project cost ₹ 7.7 million (INR).
The goal of the proposed project is to develop a tumor necrosis factor alpha (TNF-α) inhibiting first-in-class, orally bioavailable anti-neuroinflammatory small molecule drug treatment for neurocognitive dysfunction. The primary disease indication for our TNF-α inhibiting thionylated thalidomide compounds (thiothalidomides) is Alzheimer's disease (AD).

Optimization and scale-up of developed transdermal delivery system for Rheumatoid Arthritis.

The project cost ₹ 3.6 million (INR).
The project deals with the innovative skin patch as transdermal delivery system in treatment and management of Rheumatoid Arthritis.

Point of care device as decision making tool in severe Traumatic Brain Injury (sTBI) Patients.

The project cost ₹ 6.0 million (INR).
The proposed study aims to develop a rapid point-of-care (POC) prognosticative assay device which will provide clinically actionable predictive data indicating the impending onset of delayed high intracranial pressure (HICP) after a severe traumatic brain injury (sTBI).

To evaluate the toxicological properties of the novel herbal adjuvant.

The project cost ₹ 0.8 million (INR).
The project is to rule out safety & tolerability of the novel adjuvant as this vaccine is administered to healthy individuals including infants and children.